Sign in
Stories
Biopharmaceutical Merger and Presentations
Share
Biopharmaceutical Companies Merge and Pr...
4DMT Presents Positive Interim Data
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Overview
API
LENZ Therapeutics and Graphite Bio announce a merger agreement to create a late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics lead assets for the treatment of presbyopia. Opthea, a biopharmaceutical company, will present at the Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference and appoints Frederic Guerard as CEO and Peter Lang as CFO. Opthea will also participate at the 2023 Euretina Congress and feature its first-in-class VEGF-C/D trap inhibitor, OPT-302, at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting.
Ask a question
How might the merger agreement between LENZ Therapeutics and Graphite Bio impact the biopharmaceutical industry?
How might the upcoming presentations at the conferences influence the development and adoption of Opthea's therapies?
What are the potential implications of Opthea's appointments and its participation in prestigious conferences?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
Jun 2023
Aug 2023
Oct 2023
Coverage